SB207 forbids the award of any Federal funds—directly or indirectly, including through contracts and subcontracts—to an institution of higher education that hosts or is affiliated with an on‑campus clinic (a “school‑based service site”) that provides abortion drugs or performs abortions for students or employees. To remain eligible for federal funds, affected institutions must submit an annual certification to the Secretary of Education and the Secretary of Health and Human Services that no such site on their campus provides those services.
The bill also states that institutions complying with this federal condition cannot be penalized under state law solely because they complied.
Why this matters: the text reaches a broad set of campus health activities (explicitly listing telehealth and pharmaceutical services), ties eligibility for all federal funding to on‑campus clinical activity, and covers indirect funding relationships. That combination forces institutions, campus clinics, and contractors to reassess what services they offer or how they contract for care, and it raises practical questions about enforcement, the definition of “affiliated,” and what happens to student access to reproductive health care on campuses that lose or curtail services.
At a Glance
What It Does
SB207 conditions receipt of federal funds on an institution’s assurance that no on‑campus clinic it hosts or is affiliated with provides abortion drugs or abortions to students or employees. The bill bans direct and indirect federal awards (including contracts and subcontracts) to institutions that host such clinics and requires an annual certification to the Departments of Education and Health and Human Services.
Who It Affects
Public and private institutions that accept federal funds and host or are affiliated with on‑campus clinics, campus health center operators (including contracted telehealth and pharmacy providers), federal grant and contract officers, and students who rely on campus health services for reproductive care.
Why It Matters
By attaching a funding condition to campus clinical activity, the bill extends federal leverage into campus health operations and contracting. That can prompt rapid operational and contracting changes—shifting services off campus, altering vendor arrangements, or curtailing certain telehealth and pharmacy offerings—to preserve eligibility for federal dollars.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB207 creates a straightforward but wide‑ranging funding condition: if an institution of higher education hosts or is affiliated with an on‑campus clinic that provides abortion drugs or abortions to students or employees, the institution cannot receive federal funds. "Hosting" means the clinic is located on campus; "school‑based service site" in the bill explicitly includes clinics offering primary care, family planning, telehealth, and pharmaceutical services. The prohibition covers not only direct grants but also indirect awards through contracts and subcontracts.
To remain eligible, an institution with one or more covered on‑campus clinics must file an annual certification with the Secretary of Education and the Secretary of Health and Human Services stating that none of those sites provides abortion drugs or abortions to students or employees. The bill does not set out a separate enforcement apparatus or specify civil or criminal penalties; it conditions the awarding of federal funds on compliance, which places the burden on federal awarding agencies to implement and enforce the rule through grant and contract terms and through eligibility decisions.The bill’s definitions matter practically. "Abortion drug" is defined broadly to capture any drug or combination of drugs intended to intentionally end a pregnancy, but the text lists narrow exceptions—actions intended to produce a live birth, to remove a dead unborn child, or to treat an ectopic pregnancy. "School‑based service site" is limited to clinics located on campus and expressly excludes hospitals.
The text also covers telehealth and pharmaceutical services provided through those campus clinics, which means remote medication dispensing or telemedicine abortion counseling routed through an on‑campus clinic would fall within the prohibition.What the bill does not address is equally consequential. It does not define "affiliated," so institutions will need to interpret how off‑campus relationships, sponsored clinics, student health insurance networks, or referral arrangements affect eligibility.
The bill also does not address referrals, private off‑campus providers, or how to treat multi‑use drugs with several indications beyond pregnancy termination. Those gaps create uncertainty for compliance officers, campus health directors, and contracting officers deciding how to structure service delivery and vendor agreements.
The Five Things You Need to Know
SB207 prohibits any Federal funds—directly or indirectly, including through contracts and subcontracts—from being awarded to an institution that hosts or is affiliated with an on‑campus clinic that provides abortion drugs or abortions to students or employees.
An institution that hosts or is affiliated with one or more school‑based service sites must submit an annual certification to the Secretary of Education and the Secretary of Health and Human Services confirming that no such site provides abortion drugs or abortions.
The bill’s definition of “school‑based service site” explicitly includes clinics offering primary care, family planning, telehealth, and pharmaceutical services located on campus, and it expressly excludes hospitals as defined in section 1861(e) of the Social Security Act.
“Abortion drug” is defined broadly to cover any drug or combination of drugs intended to intentionally end a pregnancy, but the statute carves out three exceptions: to produce a live birth, to remove a dead unborn child, and to treat an ectopic pregnancy.
SB207 forbids State penalties against an institution solely because the institution complied with this federal condition—i.e.
it contains a preemption clause protecting federally funded institutions from state sanctions for compliance with the Act.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s short title: "Protecting Life on College Campus Act of 2025." This is a labelling provision only and has no operational effect on compliance or funding mechanisms.
Ban on federal funds for institutions hosting or affiliated with covered on‑campus clinics
This subsection is the operative funding condition: no federal funds may be awarded to any institution of higher education that hosts or is affiliated with a school‑based service site that provides abortion drugs or abortions to students or to employees. The language covers direct and indirect awards, including contracts and subcontracts, which broadens the reach beyond typical grant eligibility and requires awarding agencies to consider campus clinical activity in any funding decision.
Annual certification to Departments of Education and HHS
To remain eligible, an institution that hosts or is affiliated with one or more school‑based service sites must submit an annual certification to the Secretary of Education and the Secretary of Health and Human Services affirming that no such site provides abortion drugs or abortions to students or employees. The bill does not prescribe the certification’s form, supporting proof, or a review process, leaving those procedural details to the two agencies or later implementing guidance.
Federal compliance preempts state penalties for complying institutions
This clause states that an institution receiving federal funds may not be subject to any penalty under State law solely because it complied with the Act. Practically, the provision shields institutions from state penalties tied to following the federal condition, but it does not create affirmative immunity for individual clinicians or contractors operating under separate state regulatory regimes.
Key definitions: abortion drug, institution of higher education, school‑based service site
Defines “abortion drug” broadly to include any drug or combination intended to intentionally end a pregnancy, subject to three enumerated exceptions (produce live birth, remove a dead unborn child, treat ectopic pregnancy). It adopts the Higher Education Act definition for "institution of higher education" and defines "school‑based service site" as an on‑campus clinic providing a wide range of health care services—including telehealth and pharmaceutical services—while excluding hospitals under the Social Security Act definition. These definitions determine the provision’s scope but also leave open interpretive questions—most notably the meaning of "affiliated."
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Institutions that already prohibit abortion drugs or in‑clinic abortions on campus — they avoid operational disruption or loss of federal funding because existing practices already comply with the bill’s condition.
- Campus administrators and compliance officers at colleges with no on‑campus abortion services — they gain clarity that maintaining the status quo preserves federal funding eligibility and can document compliance via the required certification.
- Federal awarding agencies — the Departments of Education and HHS receive a clear statutory basis to condition grants and contracts on campus clinical activity, giving them a tool to enforce programmatic expectations tied to reproductive‑health policy.
- Religious or faith‑based colleges and universities that restrict certain reproductive health services — the bill reduces uncertainty about federal funding eligibility if their campus clinics do not provide abortion drugs or abortions.
Who Bears the Cost
- Campus health clinics that currently provide medication abortion, abortion procedures, telemedicine abortion counseling routed through campus clinics, or on‑campus pharmacy dispensing of abortion drugs — they face contract changes, service curtailment, or risk to the host institution’s federal funding.
- Students who rely on campus health centers for time‑sensitive reproductive care — they may lose on‑campus access to medication abortion, telehealth counseling, or pharmacy services and may face greater barriers in arranging off‑campus care.
- Institutions that affiliate with external providers or contract for student health services — because the prohibition covers indirect funding relationships, colleges may need to rework vendor contracts, move services off campus, or absorb compliance and legal costs.
- Telehealth and pharmaceutical vendors that deliver services through or under the auspices of on‑campus clinics — they risk contract loss or de‑listing if their services are construed as providing abortion drugs to students or employees.
- Departments of Education and Health and Human Services — the agencies will incur administrative burdens to process certifications, determine compliance, and incorporate the funding condition into grants and contracts without detailed procedural text in the bill.
Key Issues
The Core Tension
The central tension is between using federal funding conditions to prevent on‑campus provision of abortion drugs and abortions and the need for colleges to provide comprehensive, timely student health services: the statute protects a policy outcome through funding leverage, but that leverage can force institutions to contract, relocate, or eliminate health services, which in turn affects student access and institutional autonomy—there is no clean tradeoff that simultaneously guarantees funding certainty for institutions and uninterrupted access to all reproductive health services for students.
The bill’s reach relies heavily on several undefined or broadly phrased terms, creating implementation ambiguity. "Affiliated" is not defined, yet it appears in the operative prohibition; that single word will drive disputes over whether off‑campus clinics with campus partnerships, faculty‑run clinics, sponsored student health organizations, or services delivered under student health insurance networks count as disqualifying affiliations. Similarly, the prohibition on "indirect" federal awards—covering contracts and subcontracts—sweeps beyond traditional grant eligibility and could pull in research contracts, service contracts, and other federal buying instruments unless agencies issue narrow implementing guidance.
The statutory definition of "abortion drug" is sweeping and framed by intent (drugs "intended for use" to end pregnancy) while listing narrow exceptions. That approach raises questions about multi‑use drugs and treatments that have legitimate non‑termination indications; clinicians and compliance officers will need clear guidance on how intended use is determined and documented.
The inclusion of telehealth and pharmaceutical services further amplifies reach: a campus clinic that dispenses medication or enables a telemedicine visit coordinated through campus health could be disqualifying, which creates a strong incentive to move such services off campus. At the same time, the bill does not address referrals, off‑campus provider networks, student insurance plans, or emergency care circumstances, which could produce perverse outcomes—institutions canceling partnerships or narrowing services to reduce risk rather than designing nuanced access pathways for students.
Finally, enforcement mechanics are thin. The bill conditions funding but does not specify how agencies will verify certifications, what standard of proof will apply, whether agencies may audit campuses, or what remedial steps will follow a finding of noncompliance.
Those implementation choices will determine whether the requirement functions as a rigorous compliance regime or a compliance checkbox that produces conservative, risk‑minimizing behavior by institutions and vendors.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.